Skip to main content
OpenTrials
Completed

NCT Number: NCT03323905

Single Arm Study Using the Symphony -- MRI Guided Focused Ultrasound System for the Treatment of Leiomyomas

Single arm, first-in human feasibility study using the Symphony - MRI guided focused ultrasound system for the treatment of leiomyomas. The study is expected to accrue over 12 months. This study will help determine the feasibility to ablate leiomyomas, as measured by MR thermometry and contrast enhanced imaging. In addition, the study will look at the efficacy and safety of the treatment, as measured by the reduction in fibroid size and reduction in symptom severity score and adverse events. This study will help develop future pivotal trials using the same device.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Sunnybrook Health Sciences Centre

Toronto, Ontario, M4N3M5, Canada

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • MR-HFU device accessibility to fibroids that at least 50% of fibroid volume can be treated
  • Fibroids selected for treatment meet the following criteria
  • Total planned ablation volume of all fibroids should not exceed 500 ml AND
  • Completely non-enhancing fibroids should not be treated
  • Transformed SSS score >= 40
  • Pre- or peri-menopausal, as indicated by clinical evaluation
  • Weight < 140 kg or 310 lbs
  • Willing and able to attend all study visits
  • Willing and able to use reliable contraception methods
  • Uterine size < 24 weeks
  • Cervical cell assessment by PAP: normal, LOW Grade SIL, Low risk HPV or ASCUS subtypes of cervical tissue
  • Waist circumference <110cm or 43 inches

Exclusion criteria

  • Other Pelvic Disease (Other mass, endometriosis, ovarian tumor, acute pelvic disease, significant adenomyosis, prolonged bleeding requiring further evaluation as determined by patient's gynecologist)
  • Positive pregnancy test
  • Extensive scarring along anterior lower - abdominal wall (>50% of area)
  • Surgical clips in the potential path of the HIFU beam
  • Tattoos in the potential path of the HIFU beam
  • MRI contraindicated
  • MRI contrast agent contraindicated (including renal insufficiency)
  • Calcification around or throughout uterine tissue that may affect treatment
  • Communication barrier
  • Fibroids not quantifiable on MRI (e.g., multi-fibroid cases where volume measurements are not feasible)
  • Pedunculated fibroids
  • Bowel loops int he ultrasound beam path
  • Patients with inability to tolerate prolonged prone position for up to 3 hours
  • Patient with unstable medical conditions
  • Patients with coagulopathy or under current anti-coagulation therapy

Treatment and study plan

Symphony MRI guided High Intensity Focused Ultrasound (HIFU)

Device

The use of the MRI-HIFU for the ablation of leiomyomas

Primary outcomes

  1. The ability to ablate fibroid tissue measured by temperature elevation

    Time frame: 1 year

    Measured by MRI thermometry

  2. The ability to ablate fibroid tissue indicated by Non-Perfused Volume (NPV)

    Time frame: 1 year

    Measure by contrast enhanced imaging

  3. Safety of the system measured by collection of adverse events related to potential damage to tissue outside the treatment zone

    Time frame: 1 year

    Safety will be measured by collection of adverse events related to potential damage to tissue outside the treatment zone.

  4. Safety of the system based on damage to skin measured by collection of adverse events related to potential damage to skin over the treatment volume

    Time frame: 1 year

    Safety will be measured by collection of adverse events related to potential damage to skin over the treatment volume.

Secondary outcomes

  1. Treatment efficacy to reduce fibroid size

    Time frame: 1 year

    Reduction of fibroid volume in milliliters

  2. Treatment efficacy to reduce fibroid size by NPV

    Time frame: 1 year

    Measured by non-perfused volume in milliliters

  3. Treatment efficacy to reduce symptom severity by Symptom Severity Scores (SSS)

    Time frame: 1 year

    Change in symptoms to be quantified by Symptom Severity Scores (SSS) derived from Uterine Fibroid Symptom and Quality of Life questionnaire.

Sponsors and collaborators

Lead sponsor

Sunnybrook Health Sciences Centre

Other

Collaborators

  • Arrayus Technologies Inc.
  • Sunnybrook Research Institute

Registry information

Official study title

MRI-guided High Intensity Focused Ultrasound Ablation of Leiomyomas. Single Arm, Feasibility Study Using the Symphony - MRI Guided Focused Ultrasound System for the Treatment of Leiomyomas

Acronym: HIFUSB

Important dates

Study start
2017
Primary completion
2023
Study completion
2024
First posted
Oct 27, 2017
Registry last updated
Jul 9, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.